Picture of Tuberous Sclerosis (Periungual Fibroma)
Title: Picture of Tuberous Sclerosis (Periungual Fibroma)Category: ImagesCreated: 2/25/2010 10:10:00 AMLast Editorial Review: 6/28/2022 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - June 28, 2022 Category: Dermatology Source Type: news
First Topical Therapy for Facial Angiofibroma Nabs FDA Approval
(MedPage Today) -- The FDA approved sirolimus 0.2% gel (Hyftor) as the first topical treatment for facial angiofibroma associated with tuberous sclerosis complex (TSC), Nobelpharma announced.
The approved indication includes patients 6 years or... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - April 4, 2022 Category: Dermatology Source Type: news
FDA approves Nobelpharma's HYFTOR(TM) (sirolimus topical gel) 0.2%
HYFTOR is the first topical treatment approved by the FDA for facial angiofibroma in individuals with tuberous sclerosis complex (TSC) 6 years and older
BETHESDA, Md., April 4, 2022 -- (Healthcare Sales & Marketing Network) -- Nobelpharma America, LLC... Biopharmaceuticals, FDA Nobelpharma America, HYFTOR, sirolimus, facial angiofibroma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 4, 2022 Category: Pharmaceuticals Source Type: news
FDA Approves Hyftor (sirolimus topical gel) for Facial Angiofibroma Associated with Tuberous Sclerosis
March 22, 2022 - The U.S. Food and Drug Administration has approved Hyftor (sirolimus topical gel) for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 22, 2022 Category: Drugs & Pharmacology Source Type: news
What Are the Signs and Symptoms of Tuberous Sclerosis?
Title: What Are the Signs and Symptoms of Tuberous Sclerosis?Category: Diseases and ConditionsCreated: 9/1/2021 12:00:00 AMLast Editorial Review: 9/1/2021 12:00:00 AM (Source: MedicineNet Kids Health General)
Source: MedicineNet Kids Health General - September 1, 2021 Category: Pediatrics Source Type: news
Research team investigates causes of tuberous sclerosis
(University of M ü nster) A team of biochemists from the Faculties of Chemistry/Pharmacy and Medicine at the University of M ü nster has discovered a mechanism which regulates cell division and cell growth. The results can help to understand how Tuberous Sclerosis, a genetic disease, arises. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 12, 2021 Category: Biology Source Type: news
What Are Some Etiologies for Intellectual Disability?
Discussion
“Intellectual disability (ID) is a neurodevelopmental disorder that is characterized by deficits in both intellectual functioning and adaptive function whose onset is in the development period.” Global developmental delay (GDD) is used to describe children from 0-5 years old with significant delays in 2 or more developmental areas. These delays may be transient but up to 2/3 of children with GDD will have ID. Overall 1-3% of the general population has ID which makes it very common.
Most children with GDD/ID are identified because of delays in meeting milestones or general academic achievement. ID pat...
Source: PediatricEducation.org - May 3, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Cannabidiol Cleared for Tuberous Sclerosis Complex in Europe Cannabidiol Cleared for Tuberous Sclerosis Complex in Europe
The European Commission has approved cannabidiol for seizures associated with tuberous sclerosis complex in patients aged 2 years and older, marking the third indication in Europe.International Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 20, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
Metformin trial dramatically reduces seizures in tuberous sclerosis
(University College London) A team of researchers led by UCL Great Ormond Street Institute of Child Health (ICH) and Great Ormond Street Hospital (GOSH) has found that metformin - a drug commonly used to treat Type 2 diabetes - can successfully reduce symptoms associated with tuberous sclerosis complex (TSC), including reduction in the frequency of seizures and the size of brain tumours. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 29, 2021 Category: International Medicine & Public Health Source Type: news
Gene therapy strategy found effective in mouse model of hereditary disease TSC
(Massachusetts General Hospital) Patients with a genetic disorder called tuberous sclerosis complex have noncancerous tumors growing in numerous organs, and their treatment options are limited. A gene therapy strategy effectively treated mice that express one of the mutated genes that cause the disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 8, 2021 Category: International Medicine & Public Health Source Type: news
Management of self-injurious behavior, aggression, and psychogenic non-epileptic seizures in patients with tuberous sclerosis: a case report with a review of literature - Ortiz JF, Ruxmohan S, Gomez J, Lalama HA, Taylor A, Smith DW.
Tuberous sclerosis complex (TSC) is a neurocutaneous disorder that affects multiple systems. TSC encompasses neurobehavioral abnormalities that are considered less sensitive and specific to the disease. Autism spectrum disorder, attention deficit disorde... (Source: SafetyLit)
Source: SafetyLit - January 6, 2021 Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news
Preventive Treatment Delays Seizure Onset in Sclerosis Complex Preventive Treatment Delays Seizure Onset in Sclerosis Complex
In patients with tuberous sclerosis complex, preventive treatment with vigabatrin is safe and changes the natural history of seizures, according to research.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 22, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
FDA Approves Cannabidiol for Tuberous Sclerosis Complex FDA Approves Cannabidiol for Tuberous Sclerosis Complex
The US Food and Drug Administration has expanded its approval for cannabidiol (Epidiolex) oral solution to also treat seizures in tuberous sclerosis complex for patients aged 1 year and older.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 3, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
FDA Approves Epidiolex (cannabidiol) Oral Solution to Treat Seizures Associated with Tuberous Sclerosis Complex
CARLSBAD, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 3, 2020 Category: Drugs & Pharmacology Source Type: news
New drug pathway linked with tuberous sclerosis
(Boston Children's Hospital) Researchers in the Translational Neuroscience Center have discovered that the heat shock protein cascade may represent druggable targets for tuberous sclerosis (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 24, 2020 Category: International Medicine & Public Health Source Type: news
